It's to present Mark. a data randomized my CRDF-XXX Thank you, and Jamie, from the ONSEMBLE trial. clinical thank pleasure new you,
FOLFIRI unresectable, second-line consisting onvansertib. arm infusion. a first On trial dose colorectal following arms. the in where arms, X X with Slide see XX, XX-milligram BEV. mutated cancer BEV chemotherapy care arm In design. trial you standard patients of the enrolled RAS of measurable a FOLFIRI Patients plus can metastatic a X randomized This of the patients daily across the disease. received but included days experimental of ONSEMBLE one control of onvansertib patients was dose plus each One One one received
the rate one primary The daily as and other Phase end arm schedule response was in dosing included was Ib/II onvansertib. objective of the same The a point dose XX-milligram trial. our
the across the top enrollment you at the at been Slide XX ONSEMBLE arms. at the see can discontinue, of trial X XX, randomized Looking down that have time patients
the led any patient before withdrew post a because treated for additional never and withdrew scan. receiving was patient patient patients treated to Also trial safety prior trial consent XX baseline This patient reduces one receiving therapy. to consent Importantly, only. let available the the population and one any
were XX for patients of efficacy. not So the XX evaluable
withdrawal were patients to Both drawn so trial on any left does slides. from the arm the exposed, impact conclusions both not and the of were the following the control trial who from data bev the the randomized
On first-line BevXpose. mCRC may therapy therapy not second mean by patients include and a BEV. what In included patient simply Bev. may that enrolled is would naive did trials, whose define not or have bev-naive exactly Bev we like Slide patient XX, received already A our I'd line patients, have to prior
patients trial. only FOLFOX coming have chemotherapy into -- line received these in treatment first-line before our would second So their these patients so
In refer to trial We for line X the other the prior ONSEMBLE by evaluable for second of bev.naive. in evaluable our efficacy our our first-line included FOLFOX patients in XX bev.expose, chemotherapy. XX patients meaning addition to therapy as trial
show the with you is response IbX our want we be bev-naive observed the had trial X single-arm ONSEMBLE And past mature ONSEMBLE with on the be question trial. high excited months, over Phase the next to slide. I'm to in in patients there'll sulfur the a randomized So the continued rates results trial critical we
patient's waterfall XX. plot, response over course best to the each Slide therapy the treatment. the iis shows which of
answer question, to my the the robust see, Onvansertib patients have can to response you bev.naive once FOLFIRI bev most with plus treatment. the again, As receiving
to the the X can segregated of into Starting we XX slide, me you that allow what top patients through walk slide Now the this is from you groups. have showing. see evaluable
on arm Bev So the which these X onvansertib care FOLFIRI bev.naive FOLFIRI arm who plus onvansertib. into control data each the the cohorts, without further received left, of plus the bev.expose the bev plus on right, of we standard external patients the XX divide patients on are patients are and patients
midline size. the tumor growth the the greater represent tumor Looking the partial steel-colored at an tumor meaning bars reduction response graph, had above below objective and midline represent A the represents bar XX% the of the bars in shrinkage. patient
of you increase A a is each number. which or size. light an experimental patient numbers. on milligrams represents the slide, XX% of see bottom the either in the site patient yellow the red the bar milligrams XX can which first in between received blue patients, than of bar the boxes disease, tumor a stable a either trial dose X patients clinical XX X At on And these digits number. number of progressive above onvansertib is more is disease, represents the shown And by
left patients the our patients consistent Phase on greatest to onvansertib expected trial would standard receiving what you highly waterfall care. right our the based the on encouraging tumor data. prior from we that scan you have Ib/II see of is plot, with plus This bev-naive As observed and X shrinkage can with
additional [ conclusions. sections draw On into the next waterfall ] this slides, and few plot pass we'll
that onvansertib. out you see patients observed we observed care on plus can in -- naive responses objective As the Slide patients, of received the bev that only standard were call were we for XX,
care Given in this control and any to see that naive is the important responses randomized not without received it's on standard onvansertib. of a arm we also patients did trial, alone point bev of out
that so In X was is that site naive enrolled number, you can result coming the addition, site. patient any a not finding digits buyers by of Bev-naive of each looking first of the trial BEV a at patient different at see the out each trial single
onvansertib the bev-naive the the that in reduction XX% patient size respond, had patient received in second a patients on XX% demonstrated did Specifically reduction. tumor a and one
which more close tumor few response. question both of one details XX% your responses like as dose patients partial XX the slides. Importantly, a and had I'll have is keep responses, onvansertib onvansertib. to partial next in who this to the very naive XX% A these see I confirmed provide milligrams patients reduction for at received mind both size, these you XX-milligram a the threshold would qualify bev in in partial to and we third
in and in you observed. less what XX the effect appears we in arms, exposed And the can the of on experimental no certainly, cohort. both On patients see and objective than we were the focus responses XX, the Slide that control size Bev-naive be cohort see there to bev
see [ plots the ] we the can appear expose bev at and naive patients. on Bev-naive responses the on looking And standard have you of therapy.
On that XX, are Slide patients the to to control care bev similar arm Slide very XX, spider
control confirmed You on of in our steel patients onvansertib. left, on can the see did The the patients trajectory see arm arm the patients experimental with the responses. partial right receive on the Bev-naive to that lines not the who X the the shows plot plot -- in you allow
with arm at months control and at shrinkage patients subsequently both left scan tumor X X can the progressed their the X-month Importantly, their trial.
to the size the provide scan, scan. the suspicious like a Now mentioned lesion I Slide lung. at was new X-month in who I'd XX, metastatic in had the a reduction noted around patient earlier, context X-month On tumor XX% some this on patient's
not but a confirmed to onvansertib, infection, FOLFIRI patient on discontinue to and of unrelated cancer decided plus care physician treating the The fungal the So with new of the patient's be treating by lesion to a Bev. lung was continue tumor biopsy tier valued standard later lesion.
scan tumors to this And was patient But age tumor importantly, considered period and on plus X-month more sufficiently but was disease. the FOLFIRI any the on it progressive patient's increased X-month scan, between receiving not X-month during the onvansertib, the the for be bev. progress, when only
like on at mentioned attribute and summary, call, XX, to data. to all the have data of ONSEMBLE Slide non In the Jamie now that reiterate I'd you X Mark that seen the start the
First, second trial, our time different showing and strong than clinical it's and therapy the a Phase bev. ONSEMBLE point FOLFIRI with response was on because at in onvansertib Ib/II to trial independent have once bev naive patients a a earlier that includes again trial
objective see arm bias, Second, a all of the removing was in plus on had trial without no where bev-naive clinical we FOLFIRI randomized bev ONSEMBLE Thereby control the trial. responses. that patients onvansertib
finding Phase was the was ONSEMBLE the bev.naive look in a finally, And from the back retrospective original at designed. trial The Ib/II data. prospectively trial
signal the response naive ONSEMBLE and and prospectively we the seen before value exposed randomized between in However, to Bev in trial planned enrolling a the fashion. the differences Bev-naive have rates bev had patients
at bev toxicity is this we material, importantly, see that when that tolerated with observed. with unexpected is we plus the And data when included onvansertib well appendix safety combined no the chemotherapy in of on major that was look
Bev. On efficacy of that discovered action for of the explains you seeing are patients. mechanism start in conclude XX, why the signal This of mechanism we I'll remarks call. this clear action new naive we on reminding and Mark believe the onvansertib at we mentioned of Slide my
hypoxia discussed we due onvansertib on of in discovered robust that the August, are are detail we that believe seeing to action have a responses the novel response in As mechanism we we role pathway. for in
tumors the hypoxia-inducible stands hypoxic the on HIF in producing known hypoxic, this to protein the for Tumors starve HIF-X I well by a their that and genes become nutrients. hundreds blood of is environment. survive become supply to tumor alphaprotein, of meaning It oxygen outgrow and respond hypoxic stress tells allow factor alpha which the they
vascular A, bring mechanisms those formation nutrients cancer secreting in of to VEGFA, endothelial of One growth blood vessels cells. involve creation new of to the oxygen the tumor the to and promote factor,
separate the and Slide see HIF-X of XX, bev inhibiting of As vasculature. upstream plays you role on by But new works in by while its setting all an blocking and bev tumor its on hits angiogenic VEGF can neutralizing downstream shows onvansertib, directly VEGFA, on the on effects. thereby survival mechanisms. pathway a onvansertib creation Bev.naive This inhibiting complementary a by deploying X
as XX to my been a I've as as in signal now our conclusion, years kind In medical across oncologist, are trials. observing the clinical am never efficacy we see I excited of
to I'm this back the to Now discussion continue over hand to Jamie further. Jamie? going call
